000			01864 a2200481 4500
005			20250515211540.0
264		0	_c20100602
008			201006s 0 0 eng d
022			_a1432-0851
024	7		_a10.1007/s00262-010-0834-0 _2doi
040			_aNLM _beng _cNLM
100	1		_aLee, Sujin
245	0	0	_aOptimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors. _h[electronic resource]
260			_bCancer immunology, immunotherapy : CII _cJul 2010
300			_a1073-81 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
650	0	4	_aAnimals
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aApoptosis _xdrug effects
650	0	4	_aBoronic Acids _xadministration & dosage
650	0	4	_aBortezomib
650	0	4	_aCell Line, Tumor
650	0	4	_aDrug Synergism
650	0	4	_aFemale
650	0	4	_aMale
650	0	4	_aMammary Neoplasms, Experimental _xdrug therapy
650	0	4	_aMice
650	0	4	_aMice, Inbred BALB C
650	0	4	_aMice, Transgenic
650	0	4	_aOligodeoxyribonucleotides _xadministration & dosage
650	0	4	_aPyrazines _xadministration & dosage
650	0	4	_aRats
650	0	4	_aReceptors, TNF-Related Apoptosis-Inducing Ligand _xagonists
650	0	4	_aTNF-Related Apoptosis-Inducing Ligand _xadministration & dosage
650	0	4	_aToll-Like Receptor 9 _xagonists
650	0	4	_aTreatment Outcome
700	1		_aYagita, Hideo
700	1		_aSayers, Thomas J
700	1		_aCelis, Esteban
773	0		_tCancer immunology, immunotherapy : CII _gvol. 59 _gno. 7 _gp. 1073-81
856	4	0	_uhttps://doi.org/10.1007/s00262-010-0834-0 _zAvailable from publisher's website
999			_c19580187 _d19580187